Navigation Links
Prednisolone not benficial in most cases of community-acquired pneumonia
Date:2/23/2010

Patients hospitalized with mild to moderate community-acquired pneumonia (CAP) should not be routinely prescribed prednisolone, a corticosteroid, as it is associated with a recurrence of symptoms after its withdrawal, according to the first randomized double-blind clinical trial to address the subject.

"Prednisolone therapy next to antibiotic therapy in patients hospitalized with CAP should not be recommend due to lack of clincial benefit and a higher rate of late failures," said Dominic Snijders, M.D., lead author on the study and at the Medical Centre Alkmaar in the Netherlands.

The findings have been published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

To assess the efficacy of prednisolone therapy along with standard doctor-managed care for patients admitted to the hospital with CAP, Dr. Snijders and colleagues prospectively enrolled 213 patients who had been hospitalized with CAP and randomly assigned them to receive the usual antibiotic therapy as prescribed by their physicians supplemented with either prednisolone (40 mg dose once daily) or placebo for a week.

They found that patients on prednisolone recovered more rapidly from their fevers and had a more rapid decline in their c-reactive protein (CRP) levels than patients on placebo, indicating decreased inflammation. However, after 14 days, the patients in the prednisolone group had higher levels of CRP than the patients in the placebo group. Furthermore, three times as many patients in the prednisolone group had "late failure," defined as the recurrence of symptoms more than 72 hours after initial therapeutic success, and these patients were almost four times as likely to require additional antibiotic treatment than patients with late failure in the placebo group (6.7 percent versus 1.8 percent).

"Our study clearly shows that prednisolone therapy does not have a place in patients with CAP," said Dr. Snijders. However, he pointed out, in some cases such as when CAP is severe or occurs in conjunction with COPD, there is not enough information to draw a conclusion. Previous studies have found benefit of corticosteroid therapy among patients with severe CAP. Studies with patients with CAP and COPD have also indicated the possibility of a protective effect of prednisolone, but there have been no controlled trials.

Dr. Snijders suggested that the association of prednisolone therapy in CAP with late failures may be due to a rebound effect that could be precipitated by the abrupt withdrawal of the therapy. "Non-survivors on corticosteroid therapy died later than non-survivors without corticosteroids, respectively 13.8 versus 7.1 days," he wrote. "A tapering of the corticosteroids might protect against the rebound of inflammation."

"Further trials are indeed needed in patients with severe CAP," said Dr. Snijders. "Also, more information is needed about COPD patients, corticosteroids and pneumonia. Possible future intervention could be monoclonal TNF-alpha-antibodies or specific antibodies against other key mediators in the inflammation response. We are considering further studies in these directions."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. RAND finds cases of undiagnosed diabetes drop sharply
2. South Texas Doctors Report More Severe Cases of Community Staph Super Bug Hospitalizing Children
3. Gene profiling can single out the worst cases of multiple myeloma and guide therapy
4. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
5. HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005
6. Surge in U.S. Cases of Rocky Mountain Spotted Fever
7. The era of global aging: GSA showcases cutting-edge San Francisco meeting topics
8. Capsule endoscopy turning up undiagnosed cases of Crohns disease
9. BancTec Showcases Accounts Payable and Healthcare Solutions at The Association for Financial Professionals (AFP) Annual Conference
10. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
11. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... The Arc ... developmental disabilities (I/DD), has launched a groundbreaking LGBTQ community organization for people with special ... first organization of its kind in the state of New Jersey – but the ...
(Date:8/23/2017)... ... August 23, 2017 , ... Loyale Healthcare ... Sector Growth. Mr. Smith joins other recent high-profile hires including Frank Massi, Chief ... career began in 1993, helping physician practices and hospitals automate their clinical and ...
(Date:8/23/2017)... ... August 23, 2017 , ... Based on worldwide research and ... of HBOT in treating and helping to heal addictions and substance abuse disorders. ... similarities of the wounds to the brain from traumatic brain injuries, and the ...
(Date:8/23/2017)... ... ... Nightingale College continues the semiannual Give Back Day tradition for its fourth ... to serving and volunteering for organizations that provide indispensable resources to the community. The ... a little extra help. , The College’s Give Back Day initiative began in ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... the top 20% of hospitals nationally that earned the designation of High Performing ... overall rating of high performing indicates a hospital was significantly better than the ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology: